Memphasys

Memphasys EBIT Margin

The EBIT Margin (Operating Margin) of Memphasys (MEM.AX) as of Oct 19, 2026 is -1,516.75 %. In the previous year, EBIT Margin (Operating Margin) was -486.89 % — a change of 211.52% (lower).

EBIT Margin

-1,516.75 %

YoY

211.52%

Last updated:

EBIT Margin (Operating Margin) of Memphasys is 2026 -1,516.75 % . EBIT Margin (Operating Margin) of Memphasys was 2025 -486.89 % . It decreases by 211.52% lower compared to the previous year.

Memphasys's operating (EBIT) margin stands at -1,516.8%, up from -5,584.2% several years earlier.

The Memphasys EBIT Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT Margin
Date
EBIT Margin
Jan 1, 2015
-2,048.98 AUD
Jan 1, 2016
-2,890.40 AUD
Jan 1, 2021
-800.78 AUD
Jan 1, 2022
-5,584.19 AUD
Jan 1, 2023
-23,640.75 AUD
Jan 1, 2024
-8,731.22 AUD
Jan 1, 2025
-486.89 AUD
Jan 1, 2026
-1,516.75 AUD
The Memphasys EBIT Margin history
YEAREBIT MarginYoY
-1,516.75 %+211.52%
-486.89 %-94.42%
-8,731.22 %-63.07%
-23,640.75 %+323.35%
-5,584.19 %+597.35%
-800.78 %-72.30%
-2,890.40 %+41.07%
-2,048.98 %+991.94%
-187.65 %+5,276.07%
-3.49 %+103.61%
-1.71 %-38.10%
-2.77 %+1,884.50%
-0.14 %-91.34%
-1.61 %-59.38%
-3.97 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Memphasys Stock analysis

What does Memphasys do? Memphasys Ltd, listed on the Australian Securities Exchange under the ticker MEM.AX, is a life sciences company headquartered in Homebush West, New South Wales. The company went public via an IPO on May 14, 2007. Memphasys operates within the Health Care sector, specifically in the Life Sciences Tools & Services industry. The company focuses on developing medical devices, diagnostics, and media for applications in assisted reproduction technology (ART) for both humans and animals. Its product pipeline includes several developments, such as Felix, ROSA, and AI-Port. Felix is a patented, automated device designed to separate high-quality sperm from semen for human in vitro fertilization (IVF) procedures, aiming to avoid DNA damage. ROSA functions as an in vitro diagnostic tool to evaluate semen and blood samples for oxidative stress. AI-Port is a system for storing and transporting animal semen for artificial insemination (AI) in livestock, capable of maintaining semen viability for up to four days without freezing, which is a common practice in standard AI procedures. The company's products target global markets, particularly in the field of reproductive biotechnology, with specific applications in both human and animal reproductive health. Memphasys operates with a focus on innovation in reproductive technology, leveraging proprietary media and diagnostic tools to address challenges in assisted reproduction. Memphasys is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Memphasys stock

EBIT Margin (Operating Margin) of Memphasys is -1,516.75 % in 2026.

EBIT Margin (Operating Margin) of Memphasys changed from -486.89 % to -1,516.75 %, representing a 211.52% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBIT Margin (Operating Margin) Memphasys since 2006 – with annual values, charts, and detailed analysis.

EBIT Margin measures operating profitability as a percentage of revenue. It shows how much profit a company makes from operations before interest and taxes.

A 'good' varies by industry and company stage. On Eulerpool, you can compare EBIT Margin (Operating Margin)'s Memphasys with sector peers and the industry average to assess whether it is attractive.

To evaluate EBIT Margin (Operating Margin)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EBIT Margin (Operating Margin).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Margins — Memphasys

All Key Metrics — Memphasys